Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011854 (type 1 diabetes)
 20,749 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The premise that unexplained fetal loss is associated with maternal intravenous glucose intolerance (IVGT) has been studied retrospectively in three pregnancy related groups. In 97 women (Group A) who had stillbirths inadequately explained by obstetrical or necropsy findings, 24 per cent had abnormal IVGT tested six weeks postpartum. In 115 women (Group B) with histories of two or more spontaneous abortions (recurrent abortion) tested late in a subsequent successful pregnancy 26 per cent were abnormal. In 465 pregnancies of women with abnormal IVGT diagnosed during pregnancy (Group C) there were 19 perinatal deaths (12 stillbirths and 7 first week deaths) (Perinatal Mortality Rate 41 per 1000). Perinatal mortality characteristics which are similar to those found in insulin dependent diabetes namely a high incidence of major fetal abnormality (37 per cent) and the occurrence of hyaline membrane disease in term infants were observed. A causal association is postulated between inadequately explained stillbirth and recurrent abortion and abnormal maternal IVGT.
 ...
PMID:Fetal loss and maternal glucose intolerance. A retrospective study. 709 81

We evaluated the outcome of pregnancies followed between 1990 and 2000 in 93 women with type 1 diabetes, treated with conventional intensive insulin therapy (n=68) or continuous subcutaneous insulin infusion (n=25). We evaluated metabolic control (fasting and 1-hour post-prandial plasma glucose and HbA1c levels), spontaneous or induced abortions, time and mode of delivery, maternal outcome (pregnancy-induced hypertension, preeclampsia, placental insufficiency, hydramnios, hypoglycemic coma, ketoacidosis) and fetal outcome (weight, hypoglycemia, hypocalcemia, hyperbilirubinemia, fetal distress, asphyxia, hyaline membrane disease, polycythemia, shoulder dystocia, malformations). Patients treated with insulin pump more frequently had background retinopathy and clinical neuropathy. No significant differences were observed between the two groups in metabolic control and maternal outcome. Glycemic control, non-optimal in the prepregnancy state, improved significantly during pregnancy, as shown by the progressive reduction in HbA1c levels. As regards fetal outcome, no differences were observed between the two groups in morbidity and especially in malformation rate. Patients with malformed babies did not have optimal metabolic control at conception. Thus, maternal and perinatal outcomes were comparable in patients treated with insulin pump and continuous subcutaneous insulin therapy, and depended on metabolic control. In patients in higher White's class and with more unstable glycemia, we achieved metabolic control and outcomes comparable with those of women of lower White's class and more stable glycemic values using the insulin pump. Our data suggest that insulin pump therapy is useful in problematic, complicated cases of women who want a baby.
 ...
PMID:Analysis of outcome of pregnancy in type 1 diabetics treated with insulin pump or conventional insulin therapy. 1460 71